|drug235||Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients Wiki||1.00|
There is one clinical trial.
Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched controls.
Description: progression to critical stageMeasure: INCIDENCE OF CRITICAL PNEUMONIA Time: 14 days after convalescent plasma administration
Description: mortalityMeasure: MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS Time: 28 days after convalescent plasma administration
Description: time to need mechanical ventilationMeasure: INCIDENCE OF MECHANICAL VENTILATION Time: 14 days after convalescent plasma treatment
Description: time of mechanical ventilation neededMeasure: DAYS OF MECHANICAL VENTILATION Time: 28 days after convalescent plasma treatment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports